Skip to main navigation Contact Twitter Linkedin gbt About Our Commitment Research Our Medicine Investors & Media Careers INVESTORS & MEDIA Company Summary Media Resources Press Releases Events & Presentations Quarterly Results Analyst Coverage Stock Information SEC Filings Governance Investor FAQs Print Page RSS Feeds Email Alerts IR Contact PRESS RELEASE View printer-friendly version Back GBT Announces Participation in Upcoming Investor Conferences Nov 12, 2021 at 8:00 AM EST Download PDF SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 2:00 p.m. ET. The company will also participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference, with the fireside chat available on Monday, November 22, 2021, at 10:00 a.m. ET. The fireside chats will be available on GBT’s website at www.gbt.com in the Investors section. Replays will be archived and available for one month following each event. About Global Blood Therapeutics Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news. Contact: Steven Immergut (media) 650-410-3258 simmergut@gbt.com Courtney Roberts (investors) 650-351-7881 croberts@gbt.com Source: Global Blood Therapeutics, Inc. gbt Copyright 2021 Global Blood Therapeutics, Inc. Privacy Policy Online Tracking Opt-Out Guide Terms Of Use Community Guidelines P-VOX-US-00501 ABOUT Our Company Leadership Board of Directors Contact Us CAREERS OUR COMMITMENT Patients & Advocacy GBT’s Supported Conferences COVID-19 Information and Resources Corporate Giving Expanded Access RESEARCH Sickle Cell Disease Pipeline Partnerships Publications OUR MEDICINE INVESTORS & MEDIA Company Summary Media Resources Press Releases Events & Presentations Quarterly Results Analyst Coverage Stock Information SEC Filings Governance Investor FAQs This site uses cookies to give you the best online experience. Learn more, including how to disable certain cookies on our Privacy Page. Accept